NIPH Clinical Trials Search

JRCT ID: jRCT2031220231

Registered date:30/07/2022

A Study to Investigate the Efficacy and Safety of Faricimab in Patients with Polypoidal Choroidal Vasculopathy

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedPOLYPOIDAL CHOROIDAL VASCULOPATHY
Date of first enrollment24/04/2023
Target sample size132
Countries of recruitmentChina,Japan,Hong Kong,Japan,Singapore,Japan,Taiwan,Japan,Malaysia,Japan,South Korea,Japan,Thailand,Japan,India,Japan
Study typeInterventional
Intervention(s)faricimab: 6.0 mg of faricimab (genetical recombination) is administered by intravitreal injection once every 4-20 weeks.


Primary OutcomeEfficacy Change from baseline in BCVA based on an average at Weeks 40, 44, and 48
Secondary OutcomeSafety, Efficacy, Other Change from baseline in BCVA based on an average at Weeks 100, 104, and 108 Change from baseline in BCVA over time and proportion of participants gaining / avoiding loss of >= 15, >= 10, or >= 5 letters in BCVA from baseline over time Proportion of participants with complete polypoidal lesion regressions at Weeks 16, 48, and 108 Change from baseline in CST based on an average at Weeks 40, 44, 48, 100, 104 and 108 Change from baseline in CST over time Proportion of participants on a Q8W, Q12W, and Q16W treatment interval at Weeks 24, 44, and 108, and Q20W at Week 108 Number of faricimab injections received from Week 48 through Week 108 Incidence and severity of adverse events

Key inclusion & exclusion criteria

Age minimum>= 50age old
Age maximumNot applicable
Include criteriaSufficiently clear ocular media and adequate pupillary dilatation to allow acquisition of good quality retinal images to confirm diagnosis Confirmed diagnosis, by the investigator, of symptomatic macular PCV BCVA scores of 78-24 ETDRS letters, inclusive (20/32 to 20/320 approximate Snellen equivalent), using the ETDRS protocol and assessed at the initial testing distance of 4 meters on study Day 1 For female participants of childbearing potential: agreement to remain abstinent or use contraceptive methods with a failure rate of < 1% per year, during the treatment period and for 38 days after the final dose of faricimab
Exclude criteriaAny major illness or major surgical procedure within 1 month before screening Continuous use of any medications and treatments indicated in Prohibited Therapy Uncontrolled blood pressure on study Day 1 History of stroke (cerebral vascular accident) or myocardial infarction within 6 months prior to study Day 1 History of other disease, metabolic dysfunction, physical examination finding, or historical or current clinical laboratory findings giving reasonable suspicion of a condition that contraindicates the use of the investigational drug or that might affect interpretation of the results of the study or renders the participant at high risk for treatment complications in the opinion of the investigator History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the faricimab injection, study-related procedure preparations (including fluorescein and indocyanine green dyes), dilating drops, or any of the anesthetic and antimicrobial preparations used by a participant during the study Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 38 days after the final dose of faricimab Spherical equivalent of refractive error demonstrating more than 8 diopters of myopia (For participants who have undergone prior refractive or cataract surgery, the preoperative refractive error should not have exceeded -8 diopters of myopia.) Any cataract surgery or treatment for complications of cataract surgery with steroids or yttrium-aluminum-garnet (YAG) laser capsulotomy within 3 months prior to study Day 1 Prior periocular pharmacological or IVT treatment (including anti-VEGF medication) for other retinal diseases Any prior or concomitant treatment for PCV or other retinal diseases, including, but not restricted to, IVT treatment (e.g., faricimab, anti-VEGF, steroids, tissue plasminogen activator, ocriplasmin, C3F8, air), periocular pharmacological intervention, argon laser photocoagulation, verteporfin PDT, diode laser, transpupillary thermotherapy, or ocular surgical intervention Uncontrolled glaucoma

Related Information


Public contact
Name Clinical trials information
Address 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku Tokyo Tokyo Japan 103-8324
Telephone +81-120-189-706
Affiliation Chugai Pharmaceutical Co., Ltd.
Scientific contact
Name Nitin Jain, M.D.
Address 1-1 Nihonbashi-Muromachi 2-Chome, Chuo-ku Tokyo Tokyo Japan 103-8324
Telephone +81-120-189-706
Affiliation F. Hoffmann-La Roche Ltd